4 completed. 3 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow MK-1654: new trials by email Literature Review of MK-1654 trials Research Report on MK-1654
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) Clesrovimab, Palivizumab, Placebo - RSV Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1003 | 2021-11-30 | 2026-05-08 |
| Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) Clesrovimab, Placebo - Respiratory Syncytial Virus Infection | Phase 2 / Phase 3 | Completed | Merck Sharp & Dohme LLC | 3632 | 2021-04-07 | 2026-02-11 |
| Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005) Clesrovimab, Placebo, RSV-A Memphis 37b - Respiratory Syncytial Viruses | Phase 2 | Completed | Merck Sharp & Dohme LLC | 80 | 2019-10-28 | 2022-09-14 |
| Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) Clesrovimab, Placebo - Respiratory Tract Infection, Respiratory Syncytial Virus | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 183 | 2018-09-20 | 2025-01-14 |
Respiratory Syncytial Virus Infections (2) · Respiratory Tract Infections (1)
Chile (3) · Colombia (3) · South Africa (3) · United Kingdom (3) · United States (3) · Canada (2) · Finland (2) · France (2) · Italy (2) · Japan (2) · Malaysia (2) · Mexico (2) · Peru (2) · South Korea (2) · Spain (2)
PMID 34774184, PMID 34775220, PMID 39590882, PMID 39601265, PMID 40602662, PMID 40673795, PMID 40961423, PMID 40961446, PMID 42475081
2017 (1), 2018 (1)